查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1321527

甘露醇市场 - 预测 2023-2028

Mannitol Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 139 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021 年甘露醇市场价值为 2.094 亿美元。

甘露醇是一种糖醇或糖醇，具有低溶解度和吸湿性，既可用作甜味剂，也可用作药物。 甘露醇天然存在于树皮、新鲜蘑菇、褐藻、海藻以及大多数水果和蔬菜中。 人工生产的甘露醇通常是通过氢化果糖来生产的，而果糖是从淀粉或蔗糖中获得的。 甘露醇是一种低热量甜味剂，因为它在肠道中吸收很差。 它用于通过降低眼内压和增加颅内压来治疗青光眼。 它通过注射或吸入给药。 效果通常在 15 分钟内开始，持续长达 8 小时。

消费者的生活质量显着改善，主要得益于个人收入的增加。 随着消费者健康意识的增强，国民的饮食习惯发生了显着变化。 此外，公司投入大量时间和资源来开发由天然成分组成或专门为促进健康而设计的产品。 因此，对低热量天然甜味剂的需求不断增长正在推动预测期内全球甘露醇市场的增长。 不断增长的糖尿病人口也推动了扩张，因为甘露醇对消费者的血糖水平几乎没有影响。

然而，复杂的法律、限制、可能的副作用和知识的缺乏正在限制市场的增长。

食品、饮料和製药行业对甘露醇的需求不断增加，正在加速市场增长。

甘露醇在各种糖果产品中用作甜味剂，特别是无糖产品。 由于其溶解度低、潜热高，甘露醇广泛用于薄荷糖和泡泡糖的生产。 甘露醇吸湿性极低，在湿度达到98%之前不会吸收空气中的水分，非常适合用作硬糖、干果、巧克力涂层、口香糖等的涂层。 甘露醇优异的风味和质地使其成为咀嚼片的首选赋形剂。

甘露醇的血糖指数比蔗糖低，是糖尿病患者的甜味剂。 因此，肥胖、糖尿病、代谢综合征患者数量的增加以及消费者意识的提高正在导致甘露醇的积极扩张。 据 IDF 称，到 2021 年，糖尿病将影响 5.37 亿人。 预测显示，到 2030 年，这一数字将增至 6.43 亿，到 2045 年将增至 7.83 亿。 5.41 亿人面临患 2 型糖尿病的风险。

甘露醇还具有治疗用途。 它用于通过降低眼内压来治疗青光眼，并且在头部外伤的情况下，它可以降低颅内压。 甘露醇在欧盟 (EU) 被批准用于治疗 18 岁及以上成人的囊性纤维化。 它还可用于治疗尿量减少的肾衰竭、降低眼压、促进某些毒素的排除以及治疗液体潴留。 因此，青光眼等疾病患病率的上升可能会进一步促进甘露醇市场的扩大。 根据疾病预防控制中心的数据，大约有 300 万美国人患有青光眼。 最常见的青光眼类型是开角型青光眼，它会导致眼压升高。

预计在预测期内，亚太地区将在全球甘露醇市场中占据重要份额。

预计亚太地区将占据甘露醇市场的很大份额。 由于消费者健康意识的增强、城市化进程的加快和可支配收入的增加，该地区将在预测期内实现高速增长。 甘露醇在中国和印度等新兴市场的需求量很大。 由于饮食习惯的改变以及对低热量产品和饮料的需求不断增长，该地区的市场正在增长。 甘露醇不会影响血糖水平，使其成为糖尿病患者的绝佳选择。 因此，印度和中国等国家糖尿病患病率的上升正在推动这一领域的需求。 根据国际糖尿病联盟的数据，到 2021 年，印度将有 8.3% 的成年人（即超过 7400 万人）患有糖尿病。 到 2045 年，这一数字预计将增至 1.248 亿。 到2021年，中国13%的成年人，即超过1.4亿人将患有糖尿病。 到 2045 年，这一数字预计将增至 1.744 亿。 此外，石家庄华旭药业有限公司、新华集团有限公司和山东联盟国际贸易有限公司等主要市场参与者的渗透也推动了甘露醇在该地区的增长。 亚太地区的主要市场是印度、中国、日本、韩国、泰国、台湾和印度尼西亚。

市场趋势：

  • 2022 年 11 月，领先的製药和营养辅料製造商罗盖特 (Roquette) 宣布推出两款用于直接压片的下一代甘露醇解决方案：Pearitol CR-H 和 Pearlitol 200 GT。 这两种辅料都是专门为解决製药行业独特的配方挑战而开发的，帮助製造商优化直接压片技术，实现控释片和微片等创新，并正在扩展到各个应用领域。
  • 2020 年 3 月，SPI Pharma 宣布将 Mannogem XL Opal、Mannogem XL Ruby、Mannogem Emerald 和 Mannogem Onyx 添加到 Mannogem 甘露醇产品组合中，用于多种患者友好型口服剂型。 SPI Pharma 的新药典“甘露醇”牌号适合配製口腔崩解片和咀嚼片等患者友好剂型，可减小片剂尺寸并缩短崩解时间，从而提高患者的依从性。 它还增加了解决复杂配方挑战的选择，例如含量均匀性、低原料药可压缩性和卓越的有机性。

内容

第一章简介

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年的时间表

第二章研究方法

  • 调查数据
  • 调查过程

第 3 章执行摘要

  • 研究亮点

第 4 章市场动态

  • 市场驱动因素
  • 市场製约因素
  • 波特五力分析
  • 行业价值链分析

第五章全球甘露醇市场：按形式

  • 简介
  • 粉末
  • 颗粒

第 6 章全球甘露醇市场：按应用分类

  • 简介
  • 食物
  • 医学
  • 工业
  • 其他

第 7 章：全球甘露醇市场：按地区

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他
  • 中东/非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 以色列
    • 其他
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印度尼西亚
    • 泰国
    • 其他

第8章竞争环境与分析

  • 主要公司及战略分析
  • 新兴公司和市场盈利能力
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第9章公司简介

  • Roquette Freres Company
  • Cargill, Incorporated.
  • Ingredion Incorporated
  • SPI Pharma
  • Singsino Group Ltd.,
  • Merck Millipore Corporation
  • Bright Moon Seaweed
简介目录
Product Code: KSI061615253

The mannitol market was valued at US$209.4 million in 2021.

Mannitol is a type of sugar polyol or sugar alcohol with low solubility and hygroscopicity and is used as both a sweetener and a drug. Mannitol is naturally found in tree bark, fresh mushrooms, brown algae, seaweed, and most fruits and vegetables. Artificially mannitol is generally manufactured by hydrogenating fructose, which is derived from starch or sucrose. Since the intestines absorb it poorly, mannitol is a low-calorie sweetener. It is used to treat glaucoma by lowering ocular pressure and increasing intracranial pressure. It is administered medically by injection or inhalation. The effects usually start within 15 minutes and extend to 8 hours.

The consumer's quality of life has greatly improved, owing mostly to increased personal income. As a result of rising health consciousness among consumers, the population's eating habits have shifted substantially. Furthermore, firms are investing a lot of time and resources in developing products composed of natural ingredients and specialized goods that improve health. As a result, rising demand for low-calorie natural sweeteners is propelling the growth of the global market for mannitol throughout the projected period. The growing diabetic population is also driving expansion since mannitol has little to no effect on the consumer's blood sugar level.

However, complex laws, restrictions, possible side effects, and a lack of knowledge are restraining the market growth.

The growing demand for mannitol from the food & beverage and pharmaceutical industries is accelerating the market growth.

Mannitol is used as a sweetener in various confectionary goods, especially sugar-free products. Due to low solubility and high latent heat, mannitol is extensively used to produce mint candies and bubble gums. It has a very low hygroscopicity, meaning that it does not absorb water from the air until the humidity level reaches 98 percent, which makes it an excellent covering for hard candies, dried fruits, chocolate coatings, and chewing gums. Mannitol's excellent flavor and texture make it a preferred excipient for chewable tablets.

Mannitol has a lower glycemic index than sucrose and is a sweetener for diabetic patients. Therefore an increasing number of cases of obesity, diabetes, and metabolic syndrome, along with improved consumer awareness, has resulted in a positive expansion of mannitol. Diabetes has affected 537 million people in 2021, according to the IDF. According to forecasts, this figure is expected to rise to 643 million by 2030 and 783 million by 2045. 541 million people are at risk of developing type 2 diabetes.

Mannitol also has therapeutic applications associated with it. It is used to treat glaucoma by lowering ocular pressure and also reduces increased intracranial pressure in case of head trauma. Mannitol is approved in the European Union for treating cystic fibrosis in adults aged 18 and up. It may also treat renal failure with reduced urine production, lower eye pressure, promote the removal of certain toxins, and treat fluid buildup. Therefore, the rising prevalence of diseases such as glaucoma will even further contribute to the market expansion of mannitol. According to CDC data, Glaucoma affects around 3 million Americans. The most common type of glaucoma is open-angle, which causes increasing ocular pressure.

Asia Pacific is anticipated to hold a significant share of the global mannitol market during the forecast period.

Asia Pacific region is anticipated to hold a significant market share in mannitol. This region will witness high growth during the forecast period due to the rising health copiousness among consumers, increased urbanization, and rising disposable income. Mannitol is in high demand in rising markets such as China and India. This region's market is expanding due to changing eating habits and rising demand for low-calorie products and drinks. Mannitol does not affect blood sugar levels, making them an excellent choice for diabetic individuals. As a result, increased diabetes incidence in countries such as India and China is driving demand in this area. According to the International Diabetes Federation, 8.3 percent of Indian adults, or more than 74 million people, have been affected by diabetes in 2021. By 2045, this figure is predicted to rise to 124.8 million. Diabetes affected 13 percent of Chinese adults, or more than 140 million individuals, in 2021. By 2045, this figure is predicted to rise to 174.4 million. In addition, the prevalence of key market players such as Shijiazhuang Huaxu Pharmaceutical Co., Ltd., Singsino Group Ltd., and Shandong Lianmeng International Trade Co are also spurring the growth of mannitol in this region. Prime markets in the Asia Pacific region are India, China, Japan, South Korea, Thailand, Taiwan, and Indonesia.

Market Developments:

  • In November 2022, Roquette, a major pharmaceutical and nutraceutical excipients manufacturer, introduced two next-generation mannitol solutions for direct compression: Pearlitol CR-H and Pearlitol 200 GT. Both excipients were created specifically to address unique drug formulation issues in the pharmaceutical industry, assisting manufacturers in optimizing direct compression techniques and expanding into innovative application areas such as controlled-release tablets and tiny tabs.
  • In March 2020, SPI Pharma announced the addition of Mannogem XL Opal, Mannogem XL Ruby, Mannogem Emerald, and Mannogem Onyx to its portfolio of Mannogem Mannitol products for usage in numerous patient-friendly oral dose forms. SPI Pharma's new compendial mannitol grades are suited for the formulation of patient-friendly dosage forms such as orally-disintegrating tablets and chewable, with smaller tablet sizes and faster disintegration times, improving patient compliance. They increase the number of choices for resolving challenges with complex formulations, such as content consistency, low API compressibility, and better organoleptic.

Market Segmentation:

By Form

  • Powder
  • Granules

By Application

  • Food
  • Pharmaceuticals
  • Industrial
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL MANNITOL MARKET, BY FORM

  • 5.1. Introduction
  • 5.2. Powder
  • 5.3. Granules

6. GLOBAL MANNITOL MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Food
  • 6.3. Pharmaceuticals
  • 6.4. Industrial
  • 6.5. Others

7. GLOBAL MANNITOL MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Roquette Freres Company
  • 9.2. Cargill, Incorporated.
  • 9.3. Ingredion Incorporated
  • 9.4. SPI Pharma
  • 9.5. Singsino Group Ltd.,
  • 9.6. Merck Millipore Corporation
  • 9.7. Bright Moon Seaweed